Rosuvastatin . calcium salt
| Code | Size | Price |
|---|
| AG-CR1-3728-M010 | 10 mg | £35.00 |
Quantity:
| AG-CR1-3728-M050 | 50 mg | £60.00 |
Quantity:
| AG-CR1-3728-M250 | 250 mg | £190.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Crestor
Appearance:
White to off-white solid.
CAS:
147098-20-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/3C22H28FN3O6S.Ca/c3*1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h3*5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;;+2/p-3/b3*10-9+;/t3*16-,17-;/m111./s1
InChiKey:
VGAZDTHGPVFCCO-YFRSHGDPSA-K
Long Description:
Chemical. CAS: 147098-20-2. Formula: C22H27FN3O6S . 1/2Ca. MW: 480.6 . 20.0. Rosuvastatin is a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the ?statin? class of cholesterol-lowering drugs. Rosuvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans. Shown to have anti-inflammatory, antioxidant, antithrombotic and insulin sensitizing properties. Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
MDL:
MFCD04112702
Molecular Formula:
C22H27FN3O6S . 1/2Ca
Molecular Weight:
480.6 . 20.0
Package Type:
Vial
Product Description:
Rosuvastatin is a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the statin class of cholesterol-lowering drugs. Rosuvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans. Shown to have anti-inflammatory, antioxidant, antithrombotic and insulin sensitizing properties. Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
Purity:
>98% (HPLC)
SMILES:
CN(S(C)(=O)=O)C1=NC(C2=CC=C(F)C=C2)=C(/C=C/[C@H](C[C@@H](O)CC([O-])=O)O)C(C(C)C)=N1.[Ca+2]
Solubility Chemicals:
Soluble in DMSO (20mg/ml) or DMF (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Structural mechanism for statin inhibition of HMG-CoA reductase: E.S. Istvan & J. Deisenhofer; Science 292, 1160 (2001) | Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: F. McTaggart, et al.; Am. J. Cardiol. 87, 28B (2001) | Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor: A.G. Olsson, et al.; Cardiovasc. Drug Rev. 20, 303 (2002) (Review) | Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors: J.A. Tobert; Nat. Rev. Drug Discov. 2, 517 (2003) (Review) | Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia: A. Cheng-Lai; Heart Dis. 5, 72 (2003) (Review) | Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin: G.A. Holdgate, et al.; Biochem. Soc. Trans. 31, 528 (2003) (Review) | Rosuvastatin: a review of its effect on atherosclerosis: G.M. Keating & D.M. Robinson; Am. J. Cardiovasc. Drugs. 8, 127 (2008) (Review) | Rosuvastatin: Beyond the cholesterol-lowering effect: F. Cortese, et al.; Pharmacol. Res. 107, 1 (2016) (Review) | Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning: P. Wang, et al.; ChemRxiv (Preprint) (2020)